Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
